Allena Pharmaceuticals Inc (NASDAQ:ALNA) has coverage initiated with a Outperform ➝ Outperform rating and $20.00 price target

Analyst Ratings For Allena Pharmaceuticals Inc (NASDAQ:ALNA)

Story continues below

Today, Robert W. Baird initiated coverage on Allena Pharmaceuticals Inc (NASDAQ:ALNA) with a Outperform with a price target of $20.00.

There are 8 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Allena Pharmaceuticals Inc (NASDAQ:ALNA) is Buy with a consensus target price of $29.5714 per share, a potential 227.65% upside.

Some recent analyst ratings include

  • 1/18/2019-Allena Pharmaceuticals Inc (NASDAQ:ALNA) has coverage initiated with a Outperform ➝ Outperform rating and $20.00 price target
  • 12/30/2018-Allena Pharmaceuticals Inc (NASDAQ:ALNA) has coverage initiated with a Buy rating and $22.00 price target
  • 11/8/2018-Allena Pharmaceuticals Inc (NASDAQ:ALNA) has coverage initiated with a Buy rating and $22.00 price target
  • 10/23/2018-Allena Pharmaceuticals Inc (NASDAQ:ALNA) had its Buy rating reiterated by Wedbush with a $38.00 price target
  • 8/8/2018-Allena Pharmaceuticals Inc (NASDAQ:ALNA) had its Buy rating reiterated by Cowen
  • 8/2/2018-Allena Pharmaceuticals Inc (NASDAQ:ALNA) has coverage initiated with a Buy rating and $23.00 price target
  • 4/2/2018-Allena Pharmaceuticals Inc (NASDAQ:ALNA) has coverage initiated with a Buy ➝ Buy rating and $61.00 price target
  • On 11/6/2017 Bessemer Venture Partners Vii, Major Shareholder, bought 36,000 with an average share price of $14.00 per share and the total transaction amounting to $504,000.00.
  • On 11/6/2017 James N Topper, Director, bought 500,000 with an average share price of $14.00 per share and the total transaction amounting to $7,000,000.00.

About Allena Pharmaceuticals Inc (NASDAQ:ALNA)
Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.

Recent Trading Activity for Allena Pharmaceuticals Inc (NASDAQ:ALNA)
Shares of Allena Pharmaceuticals Inc closed the previous trading session at 9,03 +0,29 3,26 % with 8.7 shares trading hands.

An ad to help with our costs